Speaker - DDL2017

Jim Fink

Chief Science Officer Aerogen Pharma Corporation

Currently serves as Chief Scientific Officer for Aerogen Pharma Corporation in San Mateo, CA and Senior Fellow of Aerosol Device Development for Dance Biopharm in Brisbane, CA. Dr. Fink is an Adjunct Professor of Respiratory Therapy at Rush Medical School, Chicago, Texas State University and Visiting Professor, Department of Physical therapy, Universidade Federal de Pernambuco, Recife, Pernambuco, Brazil (CNPq 400801/2013-2). A respiratory care clinician, supervisor, manager, educator and researcher for 45+ years with the past 25 years dedicated to understanding aerosol device/patient interface and design in both critical care and ambulatory settings.
Jim has developed high efficiency liquid aerosol delivery systems for infants and adults, including administration of Surfactant to preterm infants and Amikacin to adults both on and off mechanical ventilation.
Dr. Fink led the development and implementation of aerosol devices for administration of inhaled measles vaccines in mass campaigns in developing countries and has been active in design development of liquid breath actuated insulin inhaler as well as systems for surfactant delivery to low birth weight infants, with multiple US and international patents.
Jim is a Registered Respiratory Therapist and Neonatal Pediatric Specialist, with a PhD in Pharmaceutical Innovation from Bradford University, UK and a Fellow of both the American Association of Respiratory Care (FAARC) and the College of Chest Physicians (FCCP). Dr. Fink has authored 3 textbooks and >120 chapters and peer reviewed papers. He serves on the editorial board for the Journal of Aerosol Medicine and Pulmonary Drug Delivery and Inhalation. He recently received the ARCF’s 2017 Forest Bird Lifetime Scientific Achievement Award.

Wednesday 6th December

Advances in aerosol delivery in intubated and non-intubated critically ill patients